Skip to content
Screener

Pre-Tax Income at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$113.38M-192%
Precigen logo
PrecigenPGEN
-$7.93M+85.4%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$91M+20.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$52.84M-34.5%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$46.47M+15.6%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$8.06M+64.9%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.38B+31.6%
Enterprise value$2.63B+33.4%
P/S2.5×-0.7×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss on extinguishment of debt(4,171)(4,171)
Other income (expense), net260(1,202)
Total other expense, net(18,991)(23,300)(38,201)(43,769)
Income (loss) before income taxes79,4746,486(641,334)7,244
Income tax expense1,0791,4012,0832,127
Net income (loss)$78,395$5,085$(643,417)$5,117
Other comprehensive (loss) income:
Foreign currency translation adjustment(27)702(89)1,068

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's pre-tax income?
BioCryst Pharmaceuticals (BCRX) reported pre-tax income of $79.47M in Q2 2026.
How has BioCryst Pharmaceuticals's pre-tax income changed year-over-year?
BioCryst Pharmaceuticals's pre-tax income increased by 1125.3% year-over-year, from $6.49M to $79.47M.
What is the long-term trend for BioCryst Pharmaceuticals's pre-tax income?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's pre-tax income has grown at a 10.1% compound annual growth rate (CAGR), from -$181.81M to $267.39M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about BioCryst Pharmaceuticals's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude